Study of EVO756 in Adults With Migraine

September 1, 2026 updated by: Evommune, Inc.

A Randomized, Double-Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of EVO756 for the Prevention of Migraine in Adults

This study will evaluate the efficacy and safety of EVO756 against placebo in adults with migraine.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

330

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • United States
    • Arizona
      • Chandler, Arizona, United States, 85286
    • California
      • Buena Park, California, United States, 90620
        • Recruiting
        • Buena Park Research Center
        • Contact:
      • Fresno, California, United States, 93710
        • Recruiting
        • Neuro Pain Research Center
        • Contact:
      • Los Angeles, California, United States, 90067
        • Recruiting
        • CA Medical Clinic for Headache
        • Contact:
      • Walnut Creek, California, United States, 94598
        • Recruiting
        • Diablo Clinical Research dba Flourish Research
        • Contact:
    • Connecticut
      • Stamford, Connecticut, United States, 06905
        • Recruiting
        • New England Institute for Neurology and Headache
        • Contact:
    • Florida
      • Jacksonville, Florida, United States, 32256
        • Recruiting
        • Clinical Neuroscience Solutions, Inc.
        • Contact:
      • Miami, Florida, United States, 33174
        • Recruiting
        • Florida Research Center, Inc.
        • Contact:
      • Miami, Florida, United States, 331216
        • Recruiting
        • Apple Medical Research Group, Inc
        • Contact:
      • Miami, Florida, United States, 33173
      • Orlando, Florida, United States, 32819
      • Tampa, Florida, United States, 33614
        • Recruiting
        • Vantage Clinical Trials
        • Contact:
      • West Palm Beach, Florida, United States, 33407
        • Recruiting
        • Premiere Research Institute at Palm Beach Neurology
        • Contact:
    • Georgia
      • Decatur, Georgia, United States, 30030
        • Recruiting
        • Accel Research Site-Decatur-Alcanza
        • Contact:
    • Massachusetts
      • Westborough, Massachusetts, United States, 01581
        • Recruiting
        • Mass Institute of Clinical Research
        • Contact:
    • Michigan
      • Ann Arbor, Michigan, United States, 48104
        • Recruiting
        • Michigan Headache and Neurological Institute
        • Contact:
      • Farmington Hills, Michigan, United States, 48334
        • Recruiting
        • Quest Research Institute-Alcanza
        • Contact:
    • New Jersey
      • Toms River, New Jersey, United States, 08755
        • Recruiting
        • Bio Behavoural health
        • Contact:
    • New York
      • Amherst, New York, United States, 14226
        • Recruiting
        • Clinosis - Dent Neurologic Instite
        • Contact:
    • North Carolina
      • Asheville, North Carolina, United States, 28806
        • Recruiting
        • Asheville Neurology Specialists, Pa
        • Contact:
      • Raleigh, North Carolina, United States, 27607
    • South Carolina
      • Charleston, South Carolina, United States, 29406
        • Recruiting
        • Clinical Trials of South Carolina
        • Contact:
    • Texas
      • Austin, Texas, United States, 78731
        • Recruiting
        • FutureSearch Trials of Neurology
        • Contact:
      • Dallas, Texas, United States, 75251
        • Recruiting
        • FutureSearch Trials of Dallas
        • Contact:
      • Houston, Texas, United States, 77018
        • Recruiting
        • SFF Medical Research Group LLC
        • Contact:
    • West Virginia
      • Crab Orchard, West Virginia, United States, 25827
        • Recruiting
        • Vaught Neurological Services
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Key Inclusion Criteria:

  • Adults aged 18 to <65 years
  • Migraine with or without aura, per ICHD-3 criteria
  • History of failure with prior preventive migraine treatments
  • Not currently using migraine preventive therapy

Key Exclusion Criteria:

  • Difficulty distinguishing migraine from other headache types or presence of other primary headache disorders
  • Use of certain medications
  • Any clinically significant medical, psychiatric, neurological, cardiovascular, or laboratory abnormalities

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Dose 1
Orally administered EVO756, Dose 1 (Daily)
Drug: EVO756, Dose 1
Orally administered EVO756, Dose 1 (Daily)
Experimental: Dose 2
Orally administered EVO756, Dose 2 (Daily)
Drug: EVO756, Dose 2
Orally administered EVO756, Dose 2 (Daily)
Placebo Comparator: Placebo
Placebo control (Daily)
Drug: Placebo
Placebo Control (Daily)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Mean change from baseline in the number of monthly migraine days (MMD)
Time Frame: Last month of the 12-week treatment period
Last month of the 12-week treatment period

Secondary Outcome Measures

Outcome Measure
Time Frame
Mean change from baseline in the number of MMD
Time Frame: Weeks 4, 8, and across the treatment period (up to 12-weeks)
Weeks 4, 8, and across the treatment period (up to 12-weeks)
Mean change from baseline in the number of monthly headache days (MHD)
Time Frame: Weeks 4, 8, 12, and across the treatment period (up to 12-weeks)
Weeks 4, 8, 12, and across the treatment period (up to 12-weeks)
Proportion of subjects achieving ≥50% and ≥75% reduction in MMD
Time Frame: Weeks 4, 8, 12, and across the treatment period (up to 12-weeks)
Weeks 4, 8, 12, and across the treatment period (up to 12-weeks)
Proportion of subjects achieving ≥50% and ≥75% reduction in MHD
Time Frame: Weeks 4, 8, 12, and across the treatment period (up to 12-weeks)
Weeks 4, 8, 12, and across the treatment period (up to 12-weeks)
Mean change from baseline in monthly acute migraine medication use days
Time Frame: Weeks 4, 8, 12, and across the treatment period (up to 12-weeks)
Weeks 4, 8, 12, and across the treatment period (up to 12-weeks)
Occurrence of treatment emergent adverse events (TEAE) and serious adverse events (SAE)
Time Frame: through Week 16
through Week 16

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Evommune, Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 29, 2026

Primary Completion (Estimated)

October 1, 2027

Study Completion (Estimated)

November 1, 2027

Study Registration Dates

First Submitted

May 19, 2026

First Submitted That Met QC Criteria

May 23, 2026

First Posted (Actual)

June 1, 2026

Study Record Updates

Last Update Posted (Actual)

September 3, 2026

Last Update Submitted That Met QC Criteria

September 1, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • EVO756-MIG001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe